We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Urigen Pharmaceuticals, Inc. is a private clinical stage urology focused specialty pharmaceutical company. Our team is focused on developing innovative products to amerliorate the cause and symtoms associated with Urological ailments, specifically Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). Our leading phase 2 program is URG101 for treating acute pain associated with IC/BPS flares. Urigen is raising $15M to fund End of Phase 2 meeting with FDA and IPO/exit activities.